Linked e-resources
Details
Table of Contents
Intro
Preface
Contents
Editor and Contributors
Chapter 1: Pseudotyped Viruses
1.1 Introduction
1.2 The Vectors for Enveloped Viruses
1.2.1 Lentiviral Vectors for Enveloped Viruses
1.2.1.1 HIV Vector
1.2.1.2 Murine Leukemia Virus Vector
1.2.1.3 FIV Vector
1.2.2 The Vesicular Stomatitis Virus Vector
1.2.2.1 VSV Reverse Genetics
1.2.2.2 Recombinant VSV Vectors
1.3 Self-Assembled Constructed Pseudotyped Viruses
1.3.1 Self-Assembled Pseudotyped Virus for Enveloped Viruses
1.3.2 Self-Assembled Pseudotyped Virus for Non-enveloped Viruses
1.4 The Parameters and Conditions for Construction and Package of Pseudotyped Viruses
1.4.1 Viral Biological Characteristic Affects Pseudotyped Virus Formation and Titer
1.4.2 The Effects of Envelope Protein Expression
1.4.3 The Effects of Packaging System
1.4.4 Effects of Proteases
1.4.5 Selection of Cell Lines for Pseudovirus Packaging and Detection
1.4.6 The Effect of Packaging Conditions
References
Chapter 2: Assays Based on Pseudotyped Viruses
2.1 Introduction
2.2 Development of In Vitro Assays Based on Pseudotyped Viruses
2.2.1 Establishment and Optimization of In Vitro Assays Based on Pseudotyped Viruses
2.2.1.1 Selection of Target Cells
2.2.1.2 Optimization of Cell Inoculation
2.2.1.3 Optimization of the Amount of Pseudotyped Virus
2.2.1.4 Optimization of Infection Conditions
2.2.1.5 Optimization of Culture Time
2.2.1.6 Validation of In Vitro Assays Based on Pseudotyped Viruses
2.2.1.7 Specificity
2.2.1.8 Accuracy
2.2.1.9 Linear Range
2.2.1.10 Precision
2.3 Development of In Vivo Assays Based on Pseudotyped Viruses
2.3.1 Selection of Model Animals
2.3.2 Optimization of Infection Pathway
2.3.3 Determination of Infection Dose of Pseudotyped Virus
2.3.4 Comparison of Pseudotyped and Live Virus Infection Model
2.4 Conclusion
References
Chapter 3: Application of Pseudotyped Viruses
3.1 Analysis of Viral Infectivity
3.1.1 Receptor Usage
3.1.2 Cellular Tropism
3.2 In Vitro Pseudovirion-Based Neutralization Assay (PBNA)
3.2.1 Development and Evaluation of Vaccines
3.2.2 Screening and Validation of Monoclonal Neutralizing Antibodies
3.3 Screening and Validation of Viral Entry Inhibitors
3.4 Animal Model of Pseudotyped Virus Infection In Vivo
3.5 Analysis of Variations in Viral Infectivity and Antigenicity
3.5.1 Viral Variants
3.5.2 Variations in Viral Glycosylation
3.6 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
3.7 Conclusion
References
Chapter 4: Pseudotyped Viruses for Retroviruses
4.1 Introduction to Retroviruses
4.2 The Retrovirus Genome and Replication Cycle: Important Regions for Retroviral Vectors
4.2.1 Genome Structure
4.2.2 Retroviral Proteins
4.2.3 Viral RNA Replication
4.3 Retroviral Pseudotyping Systems
Preface
Contents
Editor and Contributors
Chapter 1: Pseudotyped Viruses
1.1 Introduction
1.2 The Vectors for Enveloped Viruses
1.2.1 Lentiviral Vectors for Enveloped Viruses
1.2.1.1 HIV Vector
1.2.1.2 Murine Leukemia Virus Vector
1.2.1.3 FIV Vector
1.2.2 The Vesicular Stomatitis Virus Vector
1.2.2.1 VSV Reverse Genetics
1.2.2.2 Recombinant VSV Vectors
1.3 Self-Assembled Constructed Pseudotyped Viruses
1.3.1 Self-Assembled Pseudotyped Virus for Enveloped Viruses
1.3.2 Self-Assembled Pseudotyped Virus for Non-enveloped Viruses
1.4 The Parameters and Conditions for Construction and Package of Pseudotyped Viruses
1.4.1 Viral Biological Characteristic Affects Pseudotyped Virus Formation and Titer
1.4.2 The Effects of Envelope Protein Expression
1.4.3 The Effects of Packaging System
1.4.4 Effects of Proteases
1.4.5 Selection of Cell Lines for Pseudovirus Packaging and Detection
1.4.6 The Effect of Packaging Conditions
References
Chapter 2: Assays Based on Pseudotyped Viruses
2.1 Introduction
2.2 Development of In Vitro Assays Based on Pseudotyped Viruses
2.2.1 Establishment and Optimization of In Vitro Assays Based on Pseudotyped Viruses
2.2.1.1 Selection of Target Cells
2.2.1.2 Optimization of Cell Inoculation
2.2.1.3 Optimization of the Amount of Pseudotyped Virus
2.2.1.4 Optimization of Infection Conditions
2.2.1.5 Optimization of Culture Time
2.2.1.6 Validation of In Vitro Assays Based on Pseudotyped Viruses
2.2.1.7 Specificity
2.2.1.8 Accuracy
2.2.1.9 Linear Range
2.2.1.10 Precision
2.3 Development of In Vivo Assays Based on Pseudotyped Viruses
2.3.1 Selection of Model Animals
2.3.2 Optimization of Infection Pathway
2.3.3 Determination of Infection Dose of Pseudotyped Virus
2.3.4 Comparison of Pseudotyped and Live Virus Infection Model
2.4 Conclusion
References
Chapter 3: Application of Pseudotyped Viruses
3.1 Analysis of Viral Infectivity
3.1.1 Receptor Usage
3.1.2 Cellular Tropism
3.2 In Vitro Pseudovirion-Based Neutralization Assay (PBNA)
3.2.1 Development and Evaluation of Vaccines
3.2.2 Screening and Validation of Monoclonal Neutralizing Antibodies
3.3 Screening and Validation of Viral Entry Inhibitors
3.4 Animal Model of Pseudotyped Virus Infection In Vivo
3.5 Analysis of Variations in Viral Infectivity and Antigenicity
3.5.1 Viral Variants
3.5.2 Variations in Viral Glycosylation
3.6 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
3.7 Conclusion
References
Chapter 4: Pseudotyped Viruses for Retroviruses
4.1 Introduction to Retroviruses
4.2 The Retrovirus Genome and Replication Cycle: Important Regions for Retroviral Vectors
4.2.1 Genome Structure
4.2.2 Retroviral Proteins
4.2.3 Viral RNA Replication
4.3 Retroviral Pseudotyping Systems